Advanced Material Development subsidiary Com3d is embarking on a new treatment system that aims to deliver drugs directly into the lungs of Covid-19 patients.
Com3ds Texas labs, which like many in the pharma and biotech industry have remained open during the lockdown, aims to rapidly develop a drug delivery system that would use 3D-printing technology to speed the manufacturing process.
READ: Advanced Material Development re-writing the rule-book on commercialising academic research[hhmc]
Compared with existing methods of producing nanoparticles for drugs, such as emulsion evaporation, Com3d said advanced 3D printing technology can produce specific sized designed particles needed for drug delivery “in a faster more efficient process, suitable for treatment and vaccination against future seasonal and novel respiratory viruses”.
The first-of-a-kind 3D-printed, particulate drug delivery system would deliver current and future therapeutic agents and novel vaccines directly into lungs of COVID-19 patients, using a patient-specific approach, Com3d said.
“It offers significant advantages over traditional manufacturing processes including better efficiency and manufacture of personalized unit dosages.”
Delivering a vaccine by aerosol would also match the route of vaccination to the route of infection.
“The unprecedented nature of the recent COVID-19 outbreak has highlightedRead More – Source
[contf]
[contfnew]
Proactiveinvestors
[contfnewc]
[contfnewc]
